Centene(US:CNC) Thenewswire·2025-10-29 12:05Core Insights - Ventripoint Diagnostics Ltd. has partnered with Providence Health Care Ventures to validate its VMS+™ platform at St. Paul's Hospital, aiming to reduce reliance on cardiac MRI through AI-enhanced echocardiography [1][4] - The VMS+™ platform generates 3-D heart models from 2-D echocardiography images and has shown clinical agreement with MRI measurements, potentially allowing some patients to avoid MRI altogether [2][3] - The collaboration seeks to assess the performance of VMS+™ in real-world settings, focusing on workflow integration, MRI referral reductions, and cost efficiencies [4][5] Company Overview - Ventripoint is recognized for its application of AI in echocardiography, with its VMS products utilizing proprietary Knowledge Based Reconstruction technology to provide accurate cardiac measurements comparable to MRI [7][8] - The VMS+™ platform is FDA-cleared and Health Canada-licensed, compatible with existing 2D ultrasound systems, which allows healthcare systems to enhance imaging capacity without the need for new equipment [2][8] Clinical Evidence - VMS+™ has been successfully implemented in various clinical settings, including the Hospital for Sick Children and Mayo Clinic, demonstrating its effectiveness in aligning echo-derived measurements with cardiac MRI [3] - Recent presentations at conferences have highlighted the platform's ability to provide results comparable to MRI, particularly in assessing adult congenital heart defect patients [3] Future Prospects - The collaboration with PHC Ventures is set to begin in November 2025, with implementation expected in early 2026, aiming to validate the impact of VMS+™ across different healthcare settings [6] - The technology is anticipated to improve access to advanced cardiac diagnostics, especially in rural and Indigenous communities where MRI availability is limited [5][6]